Problem:Cardiovascular risk reduction in type 2 diabetes
Unchecked
This page is early; a full clinical description is coming. The cross-linked medicines below are live.
Reduction of major adverse cardiovascular events (MACE) in adults with type 2 diabetes, with or without established CVD. Basis for liraglutide (LEADER), semaglutide (SUSTAIN-6), and dulaglutide (REWIND) CV labels.